193 related articles for article (PubMed ID: 22608987)
1. The Food and Drug Administration decision not to approve the 110 mg dose of dabigatran: give us a way out.
Kowey PR; Naccarelli GV
Am J Med; 2012 Aug; 125(8):732. PubMed ID: 22608987
[No Abstract] [Full Text] [Related]
2. Dabigatran: a nephrological way out.
Pazmiño PA
Am J Med; 2013 Apr; 126(4):e21. PubMed ID: 23507214
[No Abstract] [Full Text] [Related]
3. Place of dabigatran in contemporary pharmacotherapy.
Gums JG
Pharmacotherapy; 2011 Apr; 31(4):335-7. PubMed ID: 21449622
[No Abstract] [Full Text] [Related]
4. The reply.
Kowey PR; Naccarelli GV
Am J Med; 2013 Apr; 126(4):e23. PubMed ID: 23507215
[No Abstract] [Full Text] [Related]
5. Anticoagulant options--why the FDA approved a higher but not a lower dose of dabigatran.
Beasley BN; Unger EF; Temple R
N Engl J Med; 2011 May; 364(19):1788-90. PubMed ID: 21488759
[No Abstract] [Full Text] [Related]
6. Dabigatran in patients with nonvalvular atrial fibrillation.
Gage L
J Am Coll Cardiol; 2011 Jul; 58(5):551; author reply 551. PubMed ID: 21777759
[No Abstract] [Full Text] [Related]
7. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA).
Pengo V; Crippa L; Falanga A; Finazzi G; Marongiu F; Palareti G; Poli D; Testa S; Tiraferri E; Tosetto A; Tripodi A; Manotti C;
Thromb Haemost; 2011 Nov; 106(5):868-76. PubMed ID: 21946939
[TBL] [Abstract][Full Text] [Related]
8. Dabigatran-related intracerebral hemorrhage resulting in hematoma expansion.
Simonsen CZ; Steiner T; Tietze A; Damgaard D
J Stroke Cerebrovasc Dis; 2014 Feb; 23(2):e133-4. PubMed ID: 24103671
[TBL] [Abstract][Full Text] [Related]
9. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
[TBL] [Abstract][Full Text] [Related]
10. Dabigatran and factor Xa inhibitors for stroke prevention in patients with nonvalvular atrial fibrillation.
Uchiyama S; Ibayashi S; Matsumoto M; Nagao T; Nagata K; Nakagawara J; Tanahashi N; Tanaka K; Toyoda K; Yasaka M
J Stroke Cerebrovasc Dis; 2012 Apr; 21(3):165-73. PubMed ID: 22440950
[TBL] [Abstract][Full Text] [Related]
11. Dabigatran for stroke prevention in all patients with atrial fibrillation?
Hunchuck JE; Lake JD
Pharmacotherapy; 2011 Aug; 31(8):725-8. PubMed ID: 21923597
[No Abstract] [Full Text] [Related]
12. New oral anticoagulants for non-valvular atrial fibrillation--safety issues.
Barry M
Ir Med J; 2013 Mar; 106(3):69. PubMed ID: 23951972
[No Abstract] [Full Text] [Related]
13. [Dabigatran eteksilat new anticoagulant for the prevention of stroke in patients with atrial fibrillation without valvular lesions].
Panchenko EP
Kardiologiia; 2011; 51(11):83-90. PubMed ID: 22117775
[No Abstract] [Full Text] [Related]
14. [New anticoagulants: stop or more?].
Laroche JP
J Mal Vasc; 2014 Feb; 39(1):1-3. PubMed ID: 24412008
[No Abstract] [Full Text] [Related]
15. Avoiding adverse events with dabigatran by careful selection of eligible patients.
Baker RI; Harper P; McLintock C
Med J Aust; 2012 Apr; 196(7):431-2. PubMed ID: 22509863
[No Abstract] [Full Text] [Related]
16. [New anticoagulants: "efficacy and safety" or "efficacy or safety"].
Pernod G
J Mal Vasc; 2011 Dec; 36(6):337-8. PubMed ID: 21907510
[No Abstract] [Full Text] [Related]
17. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.
Eikelboom JW; Wallentin L; Connolly SJ; Ezekowitz M; Healey JS; Oldgren J; Yang S; Alings M; Kaatz S; Hohnloser SH; Diener HC; Franzosi MG; Huber K; Reilly P; Varrone J; Yusuf S
Circulation; 2011 May; 123(21):2363-72. PubMed ID: 21576658
[TBL] [Abstract][Full Text] [Related]
18. Advances in anticoagulation: focus on dabigatran, an oral direct thrombin inhibitor.
Augoustides JG
J Cardiothorac Vasc Anesth; 2011 Dec; 25(6):1208-12. PubMed ID: 21982327
[TBL] [Abstract][Full Text] [Related]
19. The trouble with dabigatran.
Charlton B; Redberg R
BMJ; 2014 Jul; 349():g4681. PubMed ID: 25055830
[No Abstract] [Full Text] [Related]
20. Home-monitoring of oral anticoagulation vs. dabigatran. An indirect comparison.
Alonso-Coello P; Zhou Q; Guyatt G
Thromb Haemost; 2012 Oct; 108(4):647-53. PubMed ID: 22918481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
